Detalhe da pesquisa
1.
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
Blood
; 139(6): 907-921, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34601571
2.
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
N Engl J Med
; 380(22): 2095-2103, 2019 05 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31141631
3.
Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia.
Am J Hematol
; 97(5): 574-582, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35150150
4.
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients.
Am J Hematol
; 97(11): 1427-1434, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36053747
5.
Freeze-dried platelets are a promising alternative in bleeding thrombocytopenic patients with hematological malignancies.
Am J Hematol
; 97(3): 256-266, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34748664
6.
Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher.
Am J Hematol
; 97(9): 1135-1141, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35713551
7.
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.
Cancer
; 127(20): 3772-3781, 2021 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34255353
8.
Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia.
Cancer
; 127(14): 2489-2499, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33793970
9.
Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Cancer
; 127(12): 2025-2038, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33740268
10.
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
Blood
; 133(10): 1011-1019, 2019 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30530801
11.
Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia.
Haematologica
; 106(4): 1097-1105, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33297667
12.
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
Haematologica
; 106(8): 2121-2130, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33853292
13.
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
Am J Hematol
; 96(3): 282-291, 2021 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33264443
14.
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.
Blood
; 132(16): 1664-1674, 2018 10 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-30185431
15.
A heavy metal baseline score predicts outcome in acute myeloid leukemia.
Am J Hematol
; 95(4): 422-434, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31944361
16.
The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia.
Am J Hematol
; 95(10): 1127-1134, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32557828
17.
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia.
Am J Hematol
; 95(11): 1288-1295, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32681739
18.
KIT-mutated pediatric core-binding factor systemic mastocytosis-acute myeloid leukemia treated with avapritinib and decitabine.
Pediatr Blood Cancer
; 71(4): e30898, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38291730
19.
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia.
Am J Hematol
; 93(9): 1136-1141, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30028037
20.
Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
Cancer
; 123(16): 3050-3060, 2017 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28387922